Skip to main content

Emerade is an adrenaline auto-injector used for the emergency treatment of severe acute allergic reactions (anaphylaxis) to foods, medicines, insect stings, bites or other allergens. It can also be used for exercise induced anaphylaxis. (1)

Great news! Bausch & Lomb, the manufacturers of Emerade adrenaline auto-injectors (AAIs) have announced that the 300 and 500 microgram dose AAI are available again in the UK from September 2021 following corrections made to the device.

  • Emerade AAIs were recalled in 2020 because an error in one component caused some devices to fail to activate
  • Now that corrections have been made, the UK regulator has agreed that the 300 and 500 microgram strengths can be supplied in the UK again
  • The Emerade 150 microgram dose will not be available at this time (2)

BL-2382-Emerade-Patient-Leaflet-UK-2021-2-doses.pdf (

Here is a short video that demonstrates how to administer the Emerade AAI to a patient when experiencing symptoms of anaphylaxis:

It is important to remember, if there is no response to the first dose of IM Adrenaline, repeat after 5 minutes.

The recognition of anaphylaxis and the prompt administration of adrenaline is vital in saving a patient’s life so it is essential that your training is up to date.

If you would like any further training or support regarding Basic Life Support and anaphylaxis, please visit our website Courses – ECG Training to book yourself onto either an online course or face to face training.

Written by Laura Oakley (Clinical Development Manager at ECG Training) Monday 1st November 2021.


1) Patient | Emerade (

2) Emerade 300 and 500 Microgram adrenaline auto-injectors are now available again – Anaphylaxis Campaign